�й������ž���ҽԺ, a. ҩ�ﱣ������; b.ҩ���ٴ��о�����,���� 100853
Advances in the Interaction between Molecular Characteristics and Antimicrobial Activity of Carbapenem-Resistant Klebsiella pneumoniae
BAI Yana, XU Fanga, WANG Tian-lina, SUN Yana, WANG Jinb,WANG Ruib*
a. Department of Pharmaceutical Care; b. Center of Medicine Clinical Research, Chinese People��s Liberation Army General Hospital, Beijing 100853, China
Abstract��Klebsiella pneumoniae, an important nosocomial infection pathogen, has high rate of clinical isolates. Carbapenems agents is stable for the majority ��- lactamase initially, but with the broadly use of carbapenems agents, carbapenem resistant Klebsiella pneumoniae(CRKP) appear in hospital as a RESULTS , which result in the antibactic invalidation. With the CRKP rapiding growth in some area, the contents of the relevant literature review, in this article, the related literature content of the CRKP mechanism of drug resistance, molecular epidemiology and clinical antibiotic selection is reviewed, aims to explain the interaction between CRKP molecular characteristics and antimicrobial activity, also to provide theoretical basis for the more rational use of antimicrobial agents in the treatment of CRKP infection, and to investigate the CRKP different molecular mechanisms and antimicrobial activity relationship studies lay the theoretical foundation.
����,��,������,����,���,���. ̼��ùϩ��ҩ�����ײ����ķ��������뿹��ҩ���������Ե��о���չ[J]. �й�ҩѧ��־, 2016, 51(5): 346-352.
BAI Yan, XU Fang, WANG Tian-lin, SUN Yan, WANG Jin,WANG Rui. Advances in the Interaction between Molecular Characteristics and Antimicrobial Activity of Carbapenem-Resistant Klebsiella pneumoniae. Chinese Pharmaceutical Journal, 2016, 51(5): 346-352.
ZHANG W L, WANG X J, ZHAO X R, et al.Drug resistance analysis of Escherichia coli and Klebsiella pneumoniae producing beta-ESBLs[J]. Med Innov China,2015, 12(30): 105-108.
[2]
MACKENZIE F M, FORBES K J, DORAI-JOHN T, et al. Emergence of a carbapenem-resistant Klebsiella pneumoniae[J]. Lancet,1997, 350(9080): 783.
[3]
PFALLER M A, JONES R N, DOERN G V, et al. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997) [J]. Ant Agents Chemother,1998,42(7): 1762-1770.
[4]
JONES R N, KUGLER K C, PFALLER M A, et al. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program, 1997[J]. Diagn Microbiol Infect Dis, 1999, 35(1): 55-63.
[5]
HOBAN D J, BIEDENBACH D J, MUTNICK A H, et al. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: Results of the SENTRY Antimicrobial Surveillance Study (2000) [J]. Diagn Microbiol Infect Dis, 2003, 45(4): 279-285.
National report on bacterial drug resistance surveillance in 2015 [EB/OL].http://news.medlive.cn/lab/info-progress/show-88818_246.html.
[8]
NING C X, HU L H,WANG H, et al. Multi locus sequence typing of Klebsiella pneumoniae resistant Klebsiella pneumoniae[J]. Chin J Clin Pharm(�й��ٴ�ҩ��ѧ��־),2015,38(1): 17-20.
[9]
LI K, ZHAO K B, LI H, et al. Drug resistance mechanism and treatment progress of Klebsiella pneumoniae producing Klebsiella pneumoniae[J]. Chin Rem Clin, 2014, 14(6): 779-781.
[10]
WANG Q, CHEN Y. Analysis of drug resistance of Klebsiella pneumoniae resistant to carbon resistant and antibacterial drugs[J]. Pract Clin Med,2014,15(6): 20-22.
[11]
CAO L J, SHI D Y, LI Z R, et al. Analysis of drug resistance in clinical isolates of Escherichia coli in Hebei Province in 2013 the three level of first-class hospital bacterial resistance surveillance[J]. Clin Focus,2015,30(9): 970-973.
[12]
QIAO X Y, LU Q. Mechanism of Klebsiella pneumoniae resistant to the drug resistant to carbon[J]. J Clin Ped, 2015,33(10): 907-911.
[13]
ZHAO X J, DENG L H, SHI D S, et al. Molecular epidemiology and drug resistance gene analysis of Klebsiella pneumoniae resistant Klebsiella pneumoniae[J]. Int J Lab Med,2015,36(11): 1530-1532.
[14]
WU D D, CA J C, LIU J. Current status of infection of resistant Klebsiella pneumoniae[J]. Chin J Antibiot(�й���������־),2011, 36(1): 1-6.
[15]
CANDAN E D, AKS Z N. Klebsiella pneumoniae: Characteristics of carbapenem resistance and virulence factors[J].Acta Bio Polonica, 2015, 62(4): 867-874.
[16]
ZHU J, DING B, XU X, et al. Klebsiella pneumoniae: development of carbapenem resistance due to acquisition of blaNDM-1 during antimicrobial therapy in twin infants with pneumonia[J]. Front Microbiol, 2015, 6: 1399.
[17]
KAZI M, DREGO L, NIKAM C, et al. Molecular characterization of carbapenem-resistant enterobacteriaceae at a tertiary care laboratory in mumbai[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(3):467-472.
[18]
MA L, SIU L K, LIN J C, et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: First identification of KPC-2 or NDM-1-producing E. coli in Taiwan[J].BMC Infect Dis, 2013, 13(1): 599.
[19]
YIGIT H, QUEENAN A M, ANDERSON G J, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae[J]. Antimicrob Agents Chemother, 2008, 52(2): 809.
[20]
BAE I K, LEE Y N, JEONG S H, et al. Genetic and biochemical characterization of GES-5, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae[J]. Diagn Microbiol Infect Dis, 2007, 58(4): 465-468.
[21]
OSANO E, ARAKAWA Y, WACHAROTAYANKUN R, et al. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance[J]. Antimicrob Agents Chemother, 1994, 38(1): 71-78.
[22]
MIRIAGOU V, TZELEPI E, KOTSAKIS S D, et al. Combined disc methods for the detection of KPC- and/or VIM-positive Klebsiella pneumoniae: Improving reliability for the double carbapenemase producers[J]. Clin Microbiol Infect, 2013, 19(9): 412-415.
[23]
SHOMA S, KAMRUZZAMAN M, GINN A N, et al. Characterization of multidrug-resistant Klebsiella pneumoniae from Australia carrying blaNDM-1[J]. Diagn Microbiol Infect Dis, 2014, 78(1): 93-97.
[24]
ENDIMIANI A, HUJER A M, PEREZ F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA[J]. Antimicrob Chemother, 2009, 63(3): 427-437.
[25]
PARK M J, KIM T K, SONG W, et al. An increase in the clinical isolation of acquired AmpC beta-lactamase-producing Klebsiella pneumoniae in Korea from 2007 to 2010[J]. Ann Lab Med, 2013, 33(5): 353-355.
[26]
PATERSON D L, BONOMO R A.Extended-spectrum beta-lactamases: A clinical update[J]. Clin Microbiol Rev, 2005, 18(4): 657-686.
[27]
LI L, JIANG Y Q. Research progress on the mechanism of outer membrane proteins and drug resistance of Escherichia coli and Klebsiella pneumoniae[J]. J Shanghai Jiaotong Univ (Med Sci)(�Ϻ���ͨ��ѧѧ�� ҽѧ��), 2010,30(11): 1433-1436.
[28]
STOKES H W,HALL R M.A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: Integrons[J]. Mol Microbiol, 1989, 3(12):1669-1683.
[29]
PAG�HS J M, DIMARCQ J L, QUENIN S, et al. Thanatin activity on multidrug resistant clinical isolates of Enterobacter aerogenes and Klebsiella pneumoniae[J]. Int J Antimicrob Agents, 2003, 22(3):265-269.
[30]
ZHENG X. Drug resistance of Klebsiella pneumoniae isolated from clinical isolates and detection of efflux pump gene[D]. Qingdao:Qingdao Univ, 2012.
[31]
ZHUO C, SU D H, NI Y X, et al. Surveillance of drug resistance of Escherichia coli and Klebsiella pneumoniae in Chinese CHINET in 2009[J]. Chin J Infect Chemother(�й���Ⱦ�뻯����־), 2010,10(6): 430-435.
[32]
NIKAIDO H, AKATSUKA Y T. Mechanisms of RND multidrug efflux pumps[J]. Biochim Biophys Acta,2009,1794(5): 769-781.
[33]
ZHONG H Q, CAI T, ZHANG S. Research progress on the mechanism of multi drug resistance of Klebsiella pneumoniae[J]. Int J Lab Med,2012,33(6): 735-738.
[34]
PASTERAN F, MENDEZ T, RAPOPORT M, et al. Controlling false-positive results obtained with the Hodge and Masuda assays for detection of class a carbapenemase in species of enterobacteriaceae by incorporating boronic acid[J]. Clin Microbiol,2010,48(4):1323-1332.
[35]
NORDMANN P, POIREL L, DORTET L. Rapid detection of carbapenemase-producing enterobacteriaceae[J]. Emerg Infect Dis,2012, 18(9): 1503-1507.
[36]
HANG W Z, PAN X N. Progress in the study of the production of the enzyme from the bacteria of the intestinal bacteria[J]. Lab Med Clin,2015,12(12): 1798-1800.
[37]
YANG J Y, SHENG D X. Advances in the study of the prevalence and molecular characteristics of Klebsiella pneumoniae[J]. Acad J Chin PLA Med School(��ž�ҽѧԺѧ��), 2013,34(10): 1095-1097.
[38]
LIU Y, KANG M. Research progress of clinical isolates of resistant carbon resistant strains of the bacteria[J]. West China Med J(����ҽѧ), 2013,28(4):631-636.
[39]
QUEENAN A M, BUSH K. Bush carbapenemases: The versatile beta-lactamases[J]. Clin Microbiol Rev, 2007, 20(3):440-458.
[40]
SMITH MOLAND E, HANSON N D, HERRERA V L, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates[J]. J Antimicrob Chemother, 2003, 51(3): 711-714.
[41]
ZHANG W Z, HE H C, XU Z J, et al. Analysis of genotype and homology of the resistant Klebsiella pneumoniae[J]. Chin J Clin Lab Sci(�ٴ�������־), 2015,33(5):391-394.
[42]
TENOVER F C, ARBEIT R D, GOERING R V, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing[J]. J Clin Microbiol, 1995, 33(9): 2233-2239.
[43]
LIU B. Carbapenem resistant Acinetobacter Bauman molecular characteristics and study of tigecycline combined with Cefoperazone/sulbactam for its antibacterial effect[D]. Beijing: Chinese PLA Medical School, 2015.
[44]
FRANCIS R O, WU F, DELLA-LATTA P, et al. Rapid detection of Klebsiella pneumoniae carbapenemase genes in enterobacteriaceae directly from blood culture bottles by real-time PCR[J]. Am J Clin Pathol, 2012,137(4): 627-632.
[45]
WANG L L, XU J G. Application of pulsed field gel electrophoresis (PFGE) in molecular typing[J].Disease Surveillance(�������), 2006,21(5):276-279.
[46]
ALBA J, ISHII Y,THOMSON K,et al. Kinetics study of KPC-3, a plasmid-encoded class a carbapenem-hydrolyzing beta-lactamase[J]. Antimicrob Agents Chemother,2005,49(11):4760-4762.
[47]
LIU J X,YU J,LIU Y. Research progress on the resistance genes and epidemiology of Klebsiella pneumoniae producing Klebsiella pneumoniae[J].Chin J Infec Chemother(�й���Ⱦ�뻯ѧ��־),��2015,15(1):91-96.
[48]
CHEN Y, YU S S, HU Q F, et al. Detection and analysis of drug resistance genes in 69 strains of Klebsiella pneumoniae resistant Klebsiella pneumoniae[J].China Health Industry(�й�������ҵ), 2013, (10):28-30.
[49]
WEBSTER D P, GAULTON T, WOODFORD N, et al. Emergence of carbapenem resistance due to porin loss in an extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy[J].Int J Antimicrob Agents, 2010, 36(6): 575-576.
[50]
YANG D, GUO Y, ZHANG Z.Combined porin loss and extended spectrum beta-lactamase production is associated with an increasing imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains[J]. Curr Microbiol, 2009, 58(4): 366-370.
[51]
LI T, LU Y Z, LING Z H, et al. The distribution and structural analysis of the class of Klebsiella pneumoniae[J]. J Clin Transfus Lab Med(�ٴ���Ѫ�����), 2007,9(3): 197-199.
[52]
LIU J, ZHAO Z G, ZENG T, et al. Study on the relationship between AcrAB-TolC and drug resistance of Klebsiella pneumoniae in active efflux system[J]. Chin J Path Bio(�й���ԭ����ѧ��־), 2013,8(1): 35-38,70.
[53]
LING M Y, CHEN J Y, CAI Y Y et al. Study on efflux pump gene of multi drug resistant Klebsiella pneumoniae[J] . Chin J Hosp Infect(�л�ҽԺ��Ⱦѧ��־), 2010,20(8): 1055-1058.
[54]
VAN D D, KAYE K S, NEUNER E A, et al. Carbapenem-resistant Enterobacteriaceae: A review of treatment and outcomes[J]. Diagn Micro Infect Dis, 2013, 75(2): 115-120.
[55]
LI L, ZHANG X F, ZHANG J, et al. Clinical observation of treatment of 11 cases of the treatment of anti-carbon-resistant Klebsiella pneumoniae infection with phosphorus[J].China Pharm(�й�ҩҵ), 2015,24(13): 78-79
[56]
SHIELDS R K, CLANCY C J, HAO B, et al.Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae[J]. Antimicr Agents Chemother, 2015, 59(9):5793-5797.
[57]
TARRAL A, MERDJAN H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers[J]. Clin Ther, 2015, 37(4): 877-886.
[58]
AKTA Z, KAYACAN C, ONCUL O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae[J]. Int J Antimicrob Agents, 2012, 39(1): 86-89.
[59]
DAIKOS G L, TSAOUSI S, TZOUVELEKIS L S, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems[J]. Antimicrob Agents Chemother, 2014, 58(4): 2322-2328.
[60]
TASCINI C, TAGLIAFERRI E, GIANI T, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae[J].Antimicrob Agents Chemother, 2013, 57(8):3990-3993.
[61]
SANG F D. Guidelines for Antimicrobial Therapy(New Translation Forty-Third Edition)(����ҩ������ָ��)[M]. Beijing:Peking Union Medical College press, 2014: 77.
2016, Vol. 51 
